nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—type 2 diabetes mellitus—atherosclerosis	0.451	1	CtDrD
Orlistat—PLA2G7—atherosclerosis	0.367	1	CbGaD
Orlistat—CYP3A4—Rosuvastatin—atherosclerosis	0.00409	0.211	CbGbCtD
Orlistat—CYP3A4—Ezetimibe—atherosclerosis	0.00409	0.211	CbGbCtD
Orlistat—CYP3A4—Simvastatin—atherosclerosis	0.0038	0.196	CbGbCtD
Orlistat—CYP3A4—Pravastatin—atherosclerosis	0.00372	0.192	CbGbCtD
Orlistat—CYP3A4—Lovastatin—atherosclerosis	0.00372	0.192	CbGbCtD
Orlistat—Ethanolamine Oleate—FABP4—atherosclerosis	0.00275	1	CrCbGaD
Orlistat—PLA2G7—connective tissue—atherosclerosis	0.00155	0.0876	CbGeAlD
Orlistat—DAGLB—adipose tissue—atherosclerosis	0.00148	0.0832	CbGeAlD
Orlistat—PNLIP—connective tissue—atherosclerosis	0.00137	0.077	CbGeAlD
Orlistat—PLA2G7—cardiovascular system—atherosclerosis	0.00135	0.0762	CbGeAlD
Orlistat—PLA2G7—adipose tissue—atherosclerosis	0.00119	0.0672	CbGeAlD
Orlistat—PNLIP—cardiovascular system—atherosclerosis	0.00119	0.067	CbGeAlD
Orlistat—ABHD16A—adipose tissue—atherosclerosis	0.00112	0.0631	CbGeAlD
Orlistat—PNLIP—adipose tissue—atherosclerosis	0.00105	0.0591	CbGeAlD
Orlistat—ABHD12—adipose tissue—atherosclerosis	0.00105	0.0591	CbGeAlD
Orlistat—DAGLB—liver—atherosclerosis	0.00104	0.0584	CbGeAlD
Orlistat—FASN—adipose tissue—atherosclerosis	0.00088	0.0496	CbGeAlD
Orlistat—PLA2G7—liver—atherosclerosis	0.000836	0.0471	CbGeAlD
Orlistat—ABHD12—liver—atherosclerosis	0.000735	0.0415	CbGeAlD
Orlistat—PNLIP—liver—atherosclerosis	0.000735	0.0415	CbGeAlD
Orlistat—FASN—liver—atherosclerosis	0.000617	0.0348	CbGeAlD
Orlistat—PLA2G4A—connective tissue—atherosclerosis	0.000551	0.0311	CbGeAlD
Orlistat—PLA2G4A—cardiovascular system—atherosclerosis	0.00048	0.027	CbGeAlD
Orlistat—PLA2G4A—adipose tissue—atherosclerosis	0.000423	0.0238	CbGeAlD
Orlistat—Sinusitis—Lovastatin—atherosclerosis	0.000228	0.00363	CcSEcCtD
Orlistat—Depression—Simvastatin—atherosclerosis	0.000227	0.00361	CcSEcCtD
Orlistat—Pancreatitis—Pravastatin—atherosclerosis	0.000226	0.0036	CcSEcCtD
Orlistat—Mental disorder—Rosuvastatin—atherosclerosis	0.000226	0.00359	CcSEcCtD
Orlistat—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000226	0.00359	CcSEcCtD
Orlistat—Sweating increased—Pravastatin—atherosclerosis	0.000225	0.00358	CcSEcCtD
Orlistat—Sinusitis—Ezetimibe—atherosclerosis	0.000224	0.00356	CcSEcCtD
Orlistat—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000223	0.00355	CcSEcCtD
Orlistat—Flatulence—Rosuvastatin—atherosclerosis	0.000221	0.00352	CcSEcCtD
Orlistat—Hepatitis—Lovastatin—atherosclerosis	0.000218	0.00347	CcSEcCtD
Orlistat—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000215	0.00341	CcSEcCtD
Orlistat—Hepatitis—Ezetimibe—atherosclerosis	0.000214	0.00341	CcSEcCtD
Orlistat—Sinusitis—Simvastatin—atherosclerosis	0.000214	0.0034	CcSEcCtD
Orlistat—Pharyngitis—Ezetimibe—atherosclerosis	0.000213	0.00338	CcSEcCtD
Orlistat—Oedema peripheral—Ezetimibe—atherosclerosis	0.000211	0.00336	CcSEcCtD
Orlistat—Depression—Pravastatin—atherosclerosis	0.000205	0.00326	CcSEcCtD
Orlistat—Angioedema—Rosuvastatin—atherosclerosis	0.000205	0.00326	CcSEcCtD
Orlistat—Hepatitis—Simvastatin—atherosclerosis	0.000204	0.00325	CcSEcCtD
Orlistat—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000202	0.00321	CcSEcCtD
Orlistat—Urinary tract infection—Pravastatin—atherosclerosis	0.0002	0.00318	CcSEcCtD
Orlistat—Cough—Rosuvastatin—atherosclerosis	0.000196	0.00311	CcSEcCtD
Orlistat—Immune system disorder—Ezetimibe—atherosclerosis	0.000194	0.00308	CcSEcCtD
Orlistat—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000193	0.00307	CcSEcCtD
Orlistat—Sinusitis—Pravastatin—atherosclerosis	0.000193	0.00307	CcSEcCtD
Orlistat—Alopecia—Lovastatin—atherosclerosis	0.000193	0.00307	CcSEcCtD
Orlistat—Myalgia—Rosuvastatin—atherosclerosis	0.000191	0.00304	CcSEcCtD
Orlistat—Alopecia—Ezetimibe—atherosclerosis	0.000189	0.00301	CcSEcCtD
Orlistat—Haemoglobin—Niacin—atherosclerosis	0.000189	0.003	CcSEcCtD
Orlistat—Mental disorder—Ezetimibe—atherosclerosis	0.000188	0.00299	CcSEcCtD
Orlistat—Haemorrhage—Niacin—atherosclerosis	0.000188	0.00298	CcSEcCtD
Orlistat—Hepatitis—Niacin—atherosclerosis	0.000188	0.00298	CcSEcCtD
Orlistat—Flatulence—Lovastatin—atherosclerosis	0.000187	0.00298	CcSEcCtD
Orlistat—Malnutrition—Ezetimibe—atherosclerosis	0.000187	0.00297	CcSEcCtD
Orlistat—Dysgeusia—Lovastatin—atherosclerosis	0.000186	0.00296	CcSEcCtD
Orlistat—Oedema peripheral—Niacin—atherosclerosis	0.000185	0.00294	CcSEcCtD
Orlistat—Hepatitis—Pravastatin—atherosclerosis	0.000185	0.00294	CcSEcCtD
Orlistat—Back pain—Lovastatin—atherosclerosis	0.000184	0.00293	CcSEcCtD
Orlistat—Flatulence—Ezetimibe—atherosclerosis	0.000184	0.00292	CcSEcCtD
Orlistat—Pharyngitis—Pravastatin—atherosclerosis	0.000183	0.00292	CcSEcCtD
Orlistat—Muscle spasms—Lovastatin—atherosclerosis	0.000183	0.00291	CcSEcCtD
Orlistat—Infection—Rosuvastatin—atherosclerosis	0.000182	0.00289	CcSEcCtD
Orlistat—Alopecia—Simvastatin—atherosclerosis	0.000181	0.00287	CcSEcCtD
Orlistat—Back pain—Ezetimibe—atherosclerosis	0.00018	0.00287	CcSEcCtD
Orlistat—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00018	0.00286	CcSEcCtD
Orlistat—Muscle spasms—Ezetimibe—atherosclerosis	0.000179	0.00285	CcSEcCtD
Orlistat—Vision blurred—Lovastatin—atherosclerosis	0.000179	0.00285	CcSEcCtD
Orlistat—Mental disorder—Simvastatin—atherosclerosis	0.000179	0.00285	CcSEcCtD
Orlistat—Ill-defined disorder—Lovastatin—atherosclerosis	0.000176	0.00281	CcSEcCtD
Orlistat—Flatulence—Simvastatin—atherosclerosis	0.000175	0.00279	CcSEcCtD
Orlistat—Dysgeusia—Simvastatin—atherosclerosis	0.000174	0.00277	CcSEcCtD
Orlistat—Angioedema—Lovastatin—atherosclerosis	0.000174	0.00276	CcSEcCtD
Orlistat—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000173	0.00275	CcSEcCtD
Orlistat—Malaise—Lovastatin—atherosclerosis	0.000172	0.00273	CcSEcCtD
Orlistat—Muscle spasms—Simvastatin—atherosclerosis	0.000171	0.00272	CcSEcCtD
Orlistat—Vertigo—Lovastatin—atherosclerosis	0.000171	0.00272	CcSEcCtD
Orlistat—Angioedema—Ezetimibe—atherosclerosis	0.00017	0.00271	CcSEcCtD
Orlistat—Malaise—Ezetimibe—atherosclerosis	0.000168	0.00268	CcSEcCtD
Orlistat—Vision blurred—Simvastatin—atherosclerosis	0.000168	0.00267	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000167	0.00265	CcSEcCtD
Orlistat—Alopecia—Niacin—atherosclerosis	0.000166	0.00264	CcSEcCtD
Orlistat—Insomnia—Rosuvastatin—atherosclerosis	0.000166	0.00263	CcSEcCtD
Orlistat—Ill-defined disorder—Simvastatin—atherosclerosis	0.000165	0.00263	CcSEcCtD
Orlistat—Palpitations—Ezetimibe—atherosclerosis	0.000165	0.00262	CcSEcCtD
Orlistat—Paraesthesia—Rosuvastatin—atherosclerosis	0.000164	0.00262	CcSEcCtD
Orlistat—Malnutrition—Niacin—atherosclerosis	0.000163	0.0026	CcSEcCtD
Orlistat—Alopecia—Pravastatin—atherosclerosis	0.000163	0.0026	CcSEcCtD
Orlistat—Cough—Ezetimibe—atherosclerosis	0.000163	0.00259	CcSEcCtD
Orlistat—Angioedema—Simvastatin—atherosclerosis	0.000163	0.00259	CcSEcCtD
Orlistat—Chest pain—Lovastatin—atherosclerosis	0.000162	0.00258	CcSEcCtD
Orlistat—Myalgia—Lovastatin—atherosclerosis	0.000162	0.00258	CcSEcCtD
Orlistat—Anxiety—Lovastatin—atherosclerosis	0.000161	0.00257	CcSEcCtD
Orlistat—Dyspepsia—Rosuvastatin—atherosclerosis	0.000161	0.00256	CcSEcCtD
Orlistat—Flatulence—Niacin—atherosclerosis	0.000161	0.00256	CcSEcCtD
Orlistat—Malaise—Simvastatin—atherosclerosis	0.00016	0.00255	CcSEcCtD
Orlistat—Discomfort—Lovastatin—atherosclerosis	0.00016	0.00254	CcSEcCtD
Orlistat—Vertigo—Simvastatin—atherosclerosis	0.00016	0.00254	CcSEcCtD
Orlistat—Myalgia—Ezetimibe—atherosclerosis	0.000159	0.00253	CcSEcCtD
Orlistat—Chest pain—Ezetimibe—atherosclerosis	0.000159	0.00253	CcSEcCtD
Orlistat—Flatulence—Pravastatin—atherosclerosis	0.000158	0.00252	CcSEcCtD
Orlistat—Dry mouth—Lovastatin—atherosclerosis	0.000158	0.00252	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000158	0.00251	CcSEcCtD
Orlistat—Dysgeusia—Pravastatin—atherosclerosis	0.000157	0.0025	CcSEcCtD
Orlistat—Muscle spasms—Niacin—atherosclerosis	0.000157	0.0025	CcSEcCtD
Orlistat—Discomfort—Ezetimibe—atherosclerosis	0.000157	0.0025	CcSEcCtD
Orlistat—Pain—Rosuvastatin—atherosclerosis	0.000157	0.00249	CcSEcCtD
Orlistat—Dry mouth—Ezetimibe—atherosclerosis	0.000155	0.00247	CcSEcCtD
Orlistat—Anaphylactic shock—Lovastatin—atherosclerosis	0.000155	0.00247	CcSEcCtD
Orlistat—Muscle spasms—Pravastatin—atherosclerosis	0.000155	0.00246	CcSEcCtD
Orlistat—Infection—Lovastatin—atherosclerosis	0.000154	0.00245	CcSEcCtD
Orlistat—Vision blurred—Niacin—atherosclerosis	0.000154	0.00245	CcSEcCtD
Orlistat—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000152	0.00242	CcSEcCtD
Orlistat—Vision blurred—Pravastatin—atherosclerosis	0.000152	0.00241	CcSEcCtD
Orlistat—Chest pain—Simvastatin—atherosclerosis	0.000151	0.00241	CcSEcCtD
Orlistat—Myalgia—Simvastatin—atherosclerosis	0.000151	0.00241	CcSEcCtD
Orlistat—Infection—Ezetimibe—atherosclerosis	0.000151	0.00241	CcSEcCtD
Orlistat—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000151	0.0024	CcSEcCtD
Orlistat—Anxiety—Simvastatin—atherosclerosis	0.000151	0.0024	CcSEcCtD
Orlistat—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00015	0.00238	CcSEcCtD
Orlistat—Discomfort—Simvastatin—atherosclerosis	0.00015	0.00238	CcSEcCtD
Orlistat—Nervous system disorder—Ezetimibe—atherosclerosis	0.000149	0.00237	CcSEcCtD
Orlistat—Angioedema—Niacin—atherosclerosis	0.000149	0.00237	CcSEcCtD
Orlistat—Ill-defined disorder—Pravastatin—atherosclerosis	0.000149	0.00237	CcSEcCtD
Orlistat—Skin disorder—Ezetimibe—atherosclerosis	0.000148	0.00235	CcSEcCtD
Orlistat—Angioedema—Pravastatin—atherosclerosis	0.000147	0.00234	CcSEcCtD
Orlistat—Vertigo—Niacin—atherosclerosis	0.000147	0.00233	CcSEcCtD
Orlistat—Urticaria—Rosuvastatin—atherosclerosis	0.000146	0.00231	CcSEcCtD
Orlistat—Anaphylactic shock—Simvastatin—atherosclerosis	0.000145	0.00231	CcSEcCtD
Orlistat—Oedema—Simvastatin—atherosclerosis	0.000145	0.00231	CcSEcCtD
Orlistat—Malaise—Pravastatin—atherosclerosis	0.000145	0.00231	CcSEcCtD
Orlistat—Abdominal pain—Rosuvastatin—atherosclerosis	0.000145	0.0023	CcSEcCtD
Orlistat—Vertigo—Pravastatin—atherosclerosis	0.000144	0.0023	CcSEcCtD
Orlistat—Palpitations—Niacin—atherosclerosis	0.000144	0.0023	CcSEcCtD
Orlistat—Infection—Simvastatin—atherosclerosis	0.000144	0.00229	CcSEcCtD
Orlistat—Cough—Niacin—atherosclerosis	0.000143	0.00227	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000141	0.00225	CcSEcCtD
Orlistat—Insomnia—Lovastatin—atherosclerosis	0.00014	0.00223	CcSEcCtD
Orlistat—Cough—Pravastatin—atherosclerosis	0.00014	0.00223	CcSEcCtD
Orlistat—Paraesthesia—Lovastatin—atherosclerosis	0.000139	0.00222	CcSEcCtD
Orlistat—Myalgia—Niacin—atherosclerosis	0.000139	0.00221	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000139	0.00221	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000138	0.0022	CcSEcCtD
Orlistat—Insomnia—Ezetimibe—atherosclerosis	0.000138	0.00219	CcSEcCtD
Orlistat—Myalgia—Pravastatin—atherosclerosis	0.000137	0.00218	CcSEcCtD
Orlistat—Chest pain—Pravastatin—atherosclerosis	0.000137	0.00218	CcSEcCtD
Orlistat—Paraesthesia—Ezetimibe—atherosclerosis	0.000137	0.00217	CcSEcCtD
Orlistat—Dyspepsia—Lovastatin—atherosclerosis	0.000137	0.00217	CcSEcCtD
Orlistat—Anxiety—Pravastatin—atherosclerosis	0.000136	0.00217	CcSEcCtD
Orlistat—Dry mouth—Niacin—atherosclerosis	0.000136	0.00216	CcSEcCtD
Orlistat—Discomfort—Pravastatin—atherosclerosis	0.000135	0.00215	CcSEcCtD
Orlistat—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000135	0.00215	CcSEcCtD
Orlistat—Decreased appetite—Lovastatin—atherosclerosis	0.000135	0.00215	CcSEcCtD
Orlistat—Dyspepsia—Ezetimibe—atherosclerosis	0.000134	0.00213	CcSEcCtD
Orlistat—Fatigue—Lovastatin—atherosclerosis	0.000134	0.00213	CcSEcCtD
Orlistat—Oedema—Niacin—atherosclerosis	0.000133	0.00212	CcSEcCtD
Orlistat—Anaphylactic shock—Niacin—atherosclerosis	0.000133	0.00212	CcSEcCtD
Orlistat—Pain—Lovastatin—atherosclerosis	0.000133	0.00211	CcSEcCtD
Orlistat—Decreased appetite—Ezetimibe—atherosclerosis	0.000132	0.0021	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000132	0.0021	CcSEcCtD
Orlistat—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000131	0.00209	CcSEcCtD
Orlistat—Asthenia—Rosuvastatin—atherosclerosis	0.000131	0.00209	CcSEcCtD
Orlistat—Insomnia—Simvastatin—atherosclerosis	0.000131	0.00209	CcSEcCtD
Orlistat—Oedema—Pravastatin—atherosclerosis	0.000131	0.00209	CcSEcCtD
Orlistat—Anaphylactic shock—Pravastatin—atherosclerosis	0.000131	0.00209	CcSEcCtD
Orlistat—Fatigue—Ezetimibe—atherosclerosis	0.000131	0.00209	CcSEcCtD
Orlistat—Infection—Pravastatin—atherosclerosis	0.00013	0.00207	CcSEcCtD
Orlistat—Paraesthesia—Simvastatin—atherosclerosis	0.00013	0.00207	CcSEcCtD
Orlistat—Pain—Ezetimibe—atherosclerosis	0.00013	0.00207	CcSEcCtD
Orlistat—Pruritus—Rosuvastatin—atherosclerosis	0.00013	0.00206	CcSEcCtD
Orlistat—Skin disorder—Niacin—atherosclerosis	0.000129	0.00206	CcSEcCtD
Orlistat—Hyperhidrosis—Niacin—atherosclerosis	0.000129	0.00205	CcSEcCtD
Orlistat—Feeling abnormal—Lovastatin—atherosclerosis	0.000128	0.00203	CcSEcCtD
Orlistat—Dyspepsia—Simvastatin—atherosclerosis	0.000128	0.00203	CcSEcCtD
Orlistat—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000127	0.00202	CcSEcCtD
Orlistat—Hyperhidrosis—Pravastatin—atherosclerosis	0.000127	0.00202	CcSEcCtD
Orlistat—Decreased appetite—Simvastatin—atherosclerosis	0.000126	0.00201	CcSEcCtD
Orlistat—Feeling abnormal—Ezetimibe—atherosclerosis	0.000125	0.002	CcSEcCtD
Orlistat—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000125	0.00199	CcSEcCtD
Orlistat—Diarrhoea—Rosuvastatin—atherosclerosis	0.000125	0.00199	CcSEcCtD
Orlistat—Fatigue—Simvastatin—atherosclerosis	0.000125	0.00199	CcSEcCtD
Orlistat—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000124	0.00198	CcSEcCtD
Orlistat—Pain—Simvastatin—atherosclerosis	0.000124	0.00197	CcSEcCtD
Orlistat—Urticaria—Lovastatin—atherosclerosis	0.000123	0.00196	CcSEcCtD
Orlistat—Abdominal pain—Lovastatin—atherosclerosis	0.000123	0.00195	CcSEcCtD
Orlistat—Body temperature increased—Lovastatin—atherosclerosis	0.000123	0.00195	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000121	0.00193	CcSEcCtD
Orlistat—Dizziness—Rosuvastatin—atherosclerosis	0.000121	0.00193	CcSEcCtD
Orlistat—Urticaria—Ezetimibe—atherosclerosis	0.000121	0.00192	CcSEcCtD
Orlistat—Insomnia—Niacin—atherosclerosis	0.000121	0.00192	CcSEcCtD
Orlistat—Body temperature increased—Ezetimibe—atherosclerosis	0.00012	0.00191	CcSEcCtD
Orlistat—Abdominal pain—Ezetimibe—atherosclerosis	0.00012	0.00191	CcSEcCtD
Orlistat—Paraesthesia—Niacin—atherosclerosis	0.00012	0.0019	CcSEcCtD
Orlistat—Feeling abnormal—Simvastatin—atherosclerosis	0.00012	0.0019	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00012	0.0019	CcSEcCtD
Orlistat—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000119	0.00189	CcSEcCtD
Orlistat—Insomnia—Pravastatin—atherosclerosis	0.000119	0.00189	CcSEcCtD
Orlistat—Paraesthesia—Pravastatin—atherosclerosis	0.000118	0.00187	CcSEcCtD
Orlistat—Dyspepsia—Niacin—atherosclerosis	0.000117	0.00187	CcSEcCtD
Orlistat—Decreased appetite—Niacin—atherosclerosis	0.000116	0.00184	CcSEcCtD
Orlistat—Dyspepsia—Pravastatin—atherosclerosis	0.000116	0.00184	CcSEcCtD
Orlistat—Rash—Rosuvastatin—atherosclerosis	0.000115	0.00184	CcSEcCtD
Orlistat—Dermatitis—Rosuvastatin—atherosclerosis	0.000115	0.00184	CcSEcCtD
Orlistat—Urticaria—Simvastatin—atherosclerosis	0.000115	0.00183	CcSEcCtD
Orlistat—Gastrointestinal disorder—Niacin—atherosclerosis	0.000115	0.00183	CcSEcCtD
Orlistat—Body temperature increased—Simvastatin—atherosclerosis	0.000115	0.00183	CcSEcCtD
Orlistat—Abdominal pain—Simvastatin—atherosclerosis	0.000115	0.00183	CcSEcCtD
Orlistat—Headache—Rosuvastatin—atherosclerosis	0.000115	0.00182	CcSEcCtD
Orlistat—Hypersensitivity—Lovastatin—atherosclerosis	0.000114	0.00182	CcSEcCtD
Orlistat—Decreased appetite—Pravastatin—atherosclerosis	0.000114	0.00181	CcSEcCtD
Orlistat—Pain—Niacin—atherosclerosis	0.000114	0.00181	CcSEcCtD
Orlistat—Fatigue—Pravastatin—atherosclerosis	0.000113	0.0018	CcSEcCtD
Orlistat—Pain—Pravastatin—atherosclerosis	0.000112	0.00179	CcSEcCtD
Orlistat—Hypersensitivity—Ezetimibe—atherosclerosis	0.000112	0.00178	CcSEcCtD
Orlistat—Asthenia—Lovastatin—atherosclerosis	0.000111	0.00177	CcSEcCtD
Orlistat—Pruritus—Lovastatin—atherosclerosis	0.00011	0.00175	CcSEcCtD
Orlistat—Asthenia—Ezetimibe—atherosclerosis	0.000109	0.00174	CcSEcCtD
Orlistat—Gastrointestinal pain—Niacin—atherosclerosis	0.000109	0.00173	CcSEcCtD
Orlistat—Nausea—Rosuvastatin—atherosclerosis	0.000109	0.00173	CcSEcCtD
Orlistat—Feeling abnormal—Pravastatin—atherosclerosis	0.000108	0.00172	CcSEcCtD
Orlistat—Pruritus—Ezetimibe—atherosclerosis	0.000108	0.00171	CcSEcCtD
Orlistat—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000107	0.00171	CcSEcCtD
Orlistat—Hypersensitivity—Simvastatin—atherosclerosis	0.000107	0.0017	CcSEcCtD
Orlistat—Diarrhoea—Lovastatin—atherosclerosis	0.000106	0.00169	CcSEcCtD
Orlistat—Urticaria—Niacin—atherosclerosis	0.000106	0.00168	CcSEcCtD
Orlistat—Body temperature increased—Niacin—atherosclerosis	0.000105	0.00168	CcSEcCtD
Orlistat—Abdominal pain—Niacin—atherosclerosis	0.000105	0.00168	CcSEcCtD
Orlistat—Urticaria—Pravastatin—atherosclerosis	0.000104	0.00166	CcSEcCtD
Orlistat—Asthenia—Simvastatin—atherosclerosis	0.000104	0.00166	CcSEcCtD
Orlistat—Diarrhoea—Ezetimibe—atherosclerosis	0.000104	0.00166	CcSEcCtD
Orlistat—Abdominal pain—Pravastatin—atherosclerosis	0.000104	0.00165	CcSEcCtD
Orlistat—Body temperature increased—Pravastatin—atherosclerosis	0.000104	0.00165	CcSEcCtD
Orlistat—Pruritus—Simvastatin—atherosclerosis	0.000103	0.00163	CcSEcCtD
Orlistat—Dizziness—Lovastatin—atherosclerosis	0.000103	0.00163	CcSEcCtD
Orlistat—Dizziness—Ezetimibe—atherosclerosis	0.000101	0.0016	CcSEcCtD
Orlistat—Diarrhoea—Simvastatin—atherosclerosis	9.93e-05	0.00158	CcSEcCtD
Orlistat—Vomiting—Lovastatin—atherosclerosis	9.87e-05	0.00157	CcSEcCtD
Orlistat—Hypersensitivity—Niacin—atherosclerosis	9.82e-05	0.00156	CcSEcCtD
Orlistat—Rash—Lovastatin—atherosclerosis	9.79e-05	0.00156	CcSEcCtD
Orlistat—CYP3A4—liver—atherosclerosis	9.78e-05	0.00552	CbGeAlD
Orlistat—Dermatitis—Lovastatin—atherosclerosis	9.78e-05	0.00156	CcSEcCtD
Orlistat—Headache—Lovastatin—atherosclerosis	9.72e-05	0.00155	CcSEcCtD
Orlistat—Vomiting—Ezetimibe—atherosclerosis	9.68e-05	0.00154	CcSEcCtD
Orlistat—Hypersensitivity—Pravastatin—atherosclerosis	9.67e-05	0.00154	CcSEcCtD
Orlistat—Dizziness—Simvastatin—atherosclerosis	9.6e-05	0.00153	CcSEcCtD
Orlistat—Rash—Ezetimibe—atherosclerosis	9.6e-05	0.00153	CcSEcCtD
Orlistat—Dermatitis—Ezetimibe—atherosclerosis	9.59e-05	0.00153	CcSEcCtD
Orlistat—Asthenia—Niacin—atherosclerosis	9.56e-05	0.00152	CcSEcCtD
Orlistat—Headache—Ezetimibe—atherosclerosis	9.54e-05	0.00152	CcSEcCtD
Orlistat—Pruritus—Niacin—atherosclerosis	9.43e-05	0.0015	CcSEcCtD
Orlistat—Asthenia—Pravastatin—atherosclerosis	9.42e-05	0.0015	CcSEcCtD
Orlistat—Pruritus—Pravastatin—atherosclerosis	9.29e-05	0.00148	CcSEcCtD
Orlistat—Vomiting—Simvastatin—atherosclerosis	9.23e-05	0.00147	CcSEcCtD
Orlistat—Nausea—Lovastatin—atherosclerosis	9.22e-05	0.00147	CcSEcCtD
Orlistat—Rash—Simvastatin—atherosclerosis	9.15e-05	0.00146	CcSEcCtD
Orlistat—Dermatitis—Simvastatin—atherosclerosis	9.15e-05	0.00145	CcSEcCtD
Orlistat—Diarrhoea—Niacin—atherosclerosis	9.12e-05	0.00145	CcSEcCtD
Orlistat—Headache—Simvastatin—atherosclerosis	9.1e-05	0.00145	CcSEcCtD
Orlistat—Nausea—Ezetimibe—atherosclerosis	9.04e-05	0.00144	CcSEcCtD
Orlistat—Diarrhoea—Pravastatin—atherosclerosis	8.98e-05	0.00143	CcSEcCtD
Orlistat—Dizziness—Niacin—atherosclerosis	8.82e-05	0.0014	CcSEcCtD
Orlistat—Dizziness—Pravastatin—atherosclerosis	8.68e-05	0.00138	CcSEcCtD
Orlistat—Nausea—Simvastatin—atherosclerosis	8.62e-05	0.00137	CcSEcCtD
Orlistat—Vomiting—Niacin—atherosclerosis	8.48e-05	0.00135	CcSEcCtD
Orlistat—Rash—Niacin—atherosclerosis	8.41e-05	0.00134	CcSEcCtD
Orlistat—Dermatitis—Niacin—atherosclerosis	8.4e-05	0.00134	CcSEcCtD
Orlistat—Headache—Niacin—atherosclerosis	8.35e-05	0.00133	CcSEcCtD
Orlistat—Vomiting—Pravastatin—atherosclerosis	8.35e-05	0.00133	CcSEcCtD
Orlistat—Rash—Pravastatin—atherosclerosis	8.28e-05	0.00132	CcSEcCtD
Orlistat—Dermatitis—Pravastatin—atherosclerosis	8.27e-05	0.00132	CcSEcCtD
Orlistat—Headache—Pravastatin—atherosclerosis	8.22e-05	0.00131	CcSEcCtD
Orlistat—Nausea—Niacin—atherosclerosis	7.92e-05	0.00126	CcSEcCtD
Orlistat—Nausea—Pravastatin—atherosclerosis	7.8e-05	0.00124	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	9.33e-06	0.000118	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CG—atherosclerosis	9.32e-06	0.000117	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—NOS3—atherosclerosis	9.25e-06	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LPA—atherosclerosis	9.23e-06	0.000116	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARA—atherosclerosis	9.21e-06	0.000116	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—CAV1—atherosclerosis	9.16e-06	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK3—atherosclerosis	9.16e-06	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—APOA1—atherosclerosis	9.14e-06	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EDNRA—atherosclerosis	9.05e-06	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR2—atherosclerosis	9.05e-06	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—BGN—atherosclerosis	8.94e-06	0.000113	CbGpPWpGaD
Orlistat—FASN—Metabolism—AGT—atherosclerosis	8.92e-06	0.000112	CbGpPWpGaD
Orlistat—FASN—Disease—INS—atherosclerosis	8.91e-06	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—atherosclerosis	8.89e-06	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	8.87e-06	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOA5—atherosclerosis	8.85e-06	0.000111	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GHRL—atherosclerosis	8.82e-06	0.000111	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—INS—atherosclerosis	8.82e-06	0.000111	CbGpPWpGaD
Orlistat—FASN—Metabolism—APOE—atherosclerosis	8.74e-06	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—F2—atherosclerosis	8.72e-06	0.00011	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL2—atherosclerosis	8.68e-06	0.000109	CbGpPWpGaD
Orlistat—FASN—Metabolism—CAV1—atherosclerosis	8.66e-06	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL4—atherosclerosis	8.66e-06	0.000109	CbGpPWpGaD
Orlistat—FASN—Metabolism—APOA1—atherosclerosis	8.64e-06	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS2—atherosclerosis	8.62e-06	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	8.59e-06	0.000108	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IGF1—atherosclerosis	8.53e-06	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PLA2G1B—atherosclerosis	8.52e-06	0.000107	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—atherosclerosis	8.46e-06	0.000107	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	8.42e-06	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CG—atherosclerosis	8.35e-06	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	8.34e-06	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	8.32e-06	0.000105	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL8—atherosclerosis	8.28e-06	0.000104	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL8—atherosclerosis	8.28e-06	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALOX5—atherosclerosis	8.22e-06	0.000104	CbGpPWpGaD
Orlistat—FASN—Disease—SERPINE1—atherosclerosis	8.19e-06	0.000103	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SERPINE1—atherosclerosis	8.1e-06	0.000102	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOA2—atherosclerosis	8.09e-06	0.000102	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—atherosclerosis	8e-06	0.000101	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—atherosclerosis	8e-06	0.000101	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CG—atherosclerosis	7.89e-06	9.94e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—atherosclerosis	7.88e-06	9.93e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—atherosclerosis	7.88e-06	9.92e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—atherosclerosis	7.88e-06	9.92e-05	CbGpPWpGaD
Orlistat—FASN—Disease—NOS3—atherosclerosis	7.82e-06	9.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KNG1—atherosclerosis	7.74e-06	9.76e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NOS3—atherosclerosis	7.74e-06	9.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—UTS2—atherosclerosis	7.72e-06	9.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGTR1—atherosclerosis	7.7e-06	9.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IGF1—atherosclerosis	7.64e-06	9.63e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—atherosclerosis	7.61e-06	9.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	7.6e-06	9.58e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK3—atherosclerosis	7.53e-06	9.49e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—atherosclerosis	7.49e-06	9.44e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—atherosclerosis	7.49e-06	9.44e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—INS—atherosclerosis	7.47e-06	9.41e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NFKB1—atherosclerosis	7.41e-06	9.34e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NFKB1—atherosclerosis	7.41e-06	9.34e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CX3CR1—atherosclerosis	7.4e-06	9.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASR—atherosclerosis	7.4e-06	9.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NAMPT—atherosclerosis	7.38e-06	9.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	7.33e-06	9.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LIPC—atherosclerosis	7.33e-06	9.24e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFB1—atherosclerosis	7.31e-06	9.21e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK8—atherosclerosis	7.29e-06	9.18e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK8—atherosclerosis	7.29e-06	9.18e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOC3—atherosclerosis	7.29e-06	9.18e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—atherosclerosis	7.27e-06	9.16e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—atherosclerosis	7.27e-06	9.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SERPINE1—atherosclerosis	7.26e-06	9.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CX3CL1—atherosclerosis	7.25e-06	9.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ALB—atherosclerosis	7.24e-06	9.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LDLR—atherosclerosis	7.24e-06	9.12e-05	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—atherosclerosis	7.15e-06	9.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CETP—atherosclerosis	7.07e-06	8.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	6.94e-06	8.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS3—atherosclerosis	6.93e-06	8.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CNR2—atherosclerosis	6.88e-06	8.67e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL8—atherosclerosis	6.86e-06	8.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MMP3—atherosclerosis	6.86e-06	8.65e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—atherosclerosis	6.84e-06	8.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SCARB1—atherosclerosis	6.77e-06	8.53e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—atherosclerosis	6.73e-06	8.48e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—atherosclerosis	6.73e-06	8.48e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—atherosclerosis	6.66e-06	8.39e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—atherosclerosis	6.66e-06	8.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.59e-06	8.31e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—NOS3—atherosclerosis	6.55e-06	8.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EDN1—atherosclerosis	6.53e-06	8.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL5—atherosclerosis	6.48e-06	8.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMGCR—atherosclerosis	6.4e-06	8.06e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK3—atherosclerosis	6.36e-06	8.02e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK3—atherosclerosis	6.36e-06	8.02e-05	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	6.24e-06	7.86e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—atherosclerosis	6.21e-06	7.82e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	6.18e-06	7.79e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—atherosclerosis	6.17e-06	7.78e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—atherosclerosis	6.17e-06	7.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PRKCG—atherosclerosis	6.16e-06	7.76e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	6.16e-06	7.76e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NFKB1—atherosclerosis	6.14e-06	7.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VWF—atherosclerosis	6.13e-06	7.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOC3—atherosclerosis	6.09e-06	7.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LDLR—atherosclerosis	6.05e-06	7.63e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK8—atherosclerosis	6.04e-06	7.61e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—atherosclerosis	5.99e-06	7.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL3—atherosclerosis	5.91e-06	7.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.77e-06	7.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCA1—atherosclerosis	5.7e-06	7.18e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NCF1—atherosclerosis	5.66e-06	7.14e-05	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—atherosclerosis	5.58e-06	7.03e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—atherosclerosis	5.57e-06	7.02e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—atherosclerosis	5.52e-06	6.95e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—atherosclerosis	5.51e-06	6.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGT—atherosclerosis	5.42e-06	6.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EDNRA—atherosclerosis	5.35e-06	6.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR2—atherosclerosis	5.35e-06	6.74e-05	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK3—atherosclerosis	5.33e-06	6.71e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CYBA—atherosclerosis	5.32e-06	6.71e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK3—atherosclerosis	5.27e-06	6.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PARP1—atherosclerosis	5.21e-06	6.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GHRL—atherosclerosis	5.21e-06	6.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLAT—atherosclerosis	5.21e-06	6.57e-05	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—atherosclerosis	5.17e-06	6.51e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—atherosclerosis	5.12e-06	6.45e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—atherosclerosis	5.08e-06	6.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—F2—atherosclerosis	5.01e-06	6.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—atherosclerosis	4.99e-06	6.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMOX1—atherosclerosis	4.89e-06	6.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CG—atherosclerosis	4.79e-06	6.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK3—atherosclerosis	4.72e-06	5.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOB—atherosclerosis	4.69e-06	5.9e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—atherosclerosis	4.65e-06	5.86e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—atherosclerosis	4.65e-06	5.86e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—atherosclerosis	4.58e-06	5.77e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KNG1—atherosclerosis	4.57e-06	5.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—atherosclerosis	4.56e-06	5.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGTR1—atherosclerosis	4.55e-06	5.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LPL—atherosclerosis	4.47e-06	5.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL2—atherosclerosis	4.46e-06	5.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLG—atherosclerosis	4.43e-06	5.58e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	4.43e-06	5.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—atherosclerosis	4.36e-06	5.5e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—atherosclerosis	4.29e-06	5.41e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—atherosclerosis	4.29e-06	5.41e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—atherosclerosis	4.25e-06	5.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CD36—atherosclerosis	4.25e-06	5.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SOCS3—atherosclerosis	4.2e-06	5.29e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLTP—atherosclerosis	4.16e-06	5.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP3—atherosclerosis	4.05e-06	5.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF2—atherosclerosis	4.04e-06	5.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—atherosclerosis	4.03e-06	5.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARA—atherosclerosis	3.95e-06	4.98e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOB—atherosclerosis	3.92e-06	4.94e-05	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—atherosclerosis	3.89e-06	4.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EDN1—atherosclerosis	3.86e-06	4.86e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—atherosclerosis	3.86e-06	4.86e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AGT—atherosclerosis	3.83e-06	4.82e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL5—atherosclerosis	3.83e-06	4.82e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOE—atherosclerosis	3.75e-06	4.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LPL—atherosclerosis	3.74e-06	4.71e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAV1—atherosclerosis	3.72e-06	4.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOA1—atherosclerosis	3.71e-06	4.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKCG—atherosclerosis	3.64e-06	4.58e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCG8—atherosclerosis	3.61e-06	4.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LTA4H—atherosclerosis	3.61e-06	4.55e-05	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—atherosclerosis	3.59e-06	4.53e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—atherosclerosis	3.56e-06	4.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPP1—atherosclerosis	3.54e-06	4.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—atherosclerosis	3.53e-06	4.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CG—atherosclerosis	3.38e-06	4.26e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDGFB—atherosclerosis	3.28e-06	4.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—atherosclerosis	3.27e-06	4.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—INS—atherosclerosis	3.2e-06	4.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGT—atherosclerosis	3.2e-06	4.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—atherosclerosis	3.19e-06	4.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOE—atherosclerosis	3.14e-06	3.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LEP—atherosclerosis	3.14e-06	3.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CAV1—atherosclerosis	3.11e-06	3.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOA1—atherosclerosis	3.1e-06	3.91e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—atherosclerosis	3.01e-06	3.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—atherosclerosis	2.99e-06	3.77e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—F2—atherosclerosis	2.96e-06	3.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—atherosclerosis	2.94e-06	3.7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCG1—atherosclerosis	2.85e-06	3.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CG—atherosclerosis	2.83e-06	3.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NOS3—atherosclerosis	2.81e-06	3.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK3—atherosclerosis	2.71e-06	3.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LCAT—atherosclerosis	2.68e-06	3.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FABP4—atherosclerosis	2.68e-06	3.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INS—atherosclerosis	2.68e-06	3.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL2—atherosclerosis	2.64e-06	3.32e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOA4—atherosclerosis	2.63e-06	3.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—atherosclerosis	2.59e-06	3.26e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP7A1—atherosclerosis	2.59e-06	3.26e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—atherosclerosis	2.57e-06	3.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SERPINE1—atherosclerosis	2.46e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP27A1—atherosclerosis	2.39e-06	3.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOS3—atherosclerosis	2.35e-06	2.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	2.27e-06	2.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALOX15—atherosclerosis	2.27e-06	2.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOA2—atherosclerosis	2.27e-06	2.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	2.27e-06	2.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.24e-06	2.82e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LPA—atherosclerosis	2.16e-06	2.72e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BGN—atherosclerosis	2.09e-06	2.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—atherosclerosis	2.08e-06	2.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOA5—atherosclerosis	2.07e-06	2.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.99e-06	2.51e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—atherosclerosis	1.98e-06	2.5e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.93e-06	2.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—atherosclerosis	1.88e-06	2.37e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NFKB1—atherosclerosis	1.86e-06	2.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK8—atherosclerosis	1.83e-06	2.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—atherosclerosis	1.83e-06	2.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.73e-06	2.18e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LIPC—atherosclerosis	1.72e-06	2.16e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOC3—atherosclerosis	1.71e-06	2.15e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LDLR—atherosclerosis	1.7e-06	2.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—atherosclerosis	1.69e-06	2.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—atherosclerosis	1.68e-06	2.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CETP—atherosclerosis	1.66e-06	2.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK3—atherosclerosis	1.6e-06	2.02e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.59e-06	2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—atherosclerosis	1.55e-06	1.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.5e-06	1.89e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.34e-06	1.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—atherosclerosis	1.29e-06	1.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—atherosclerosis	1.17e-06	1.47e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.15e-06	1.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOB—atherosclerosis	1.1e-06	1.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—atherosclerosis	1.08e-06	1.36e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.07e-06	1.34e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LPL—atherosclerosis	1.05e-06	1.32e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—atherosclerosis	1.02e-06	1.29e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CD36—atherosclerosis	9.95e-07	1.25e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—atherosclerosis	9.43e-07	1.19e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARA—atherosclerosis	9.25e-07	1.17e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AGT—atherosclerosis	8.96e-07	1.13e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOE—atherosclerosis	8.78e-07	1.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAV1—atherosclerosis	8.7e-07	1.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOA1—atherosclerosis	8.68e-07	1.09e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CG—atherosclerosis	7.93e-07	9.99e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—atherosclerosis	7.65e-07	9.64e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—INS—atherosclerosis	7.5e-07	9.45e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—atherosclerosis	6.88e-07	8.67e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NOS3—atherosclerosis	6.58e-07	8.29e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—atherosclerosis	6.02e-07	7.58e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—atherosclerosis	3.02e-07	3.81e-06	CbGpPWpGaD
